Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis.
The main question the study aims to answer is:
• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis.
The study also aims to answer:
• Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis.
Study participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only.
The study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RABI-767 plus Standard-of-Care | Experimental | Single-dose 125 mg RABI-767 plus standard-of-care |
|
| Standard-of-Care Only | No Intervention | No Intervention, Standard-of-Care Only |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RABI-767 | Drug | 125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants with Adverse Events | An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the study intervention, regardless of its causal relationship to the study intervention. For the purposes of this study, any AE occurring in any study participant (regardless of treatment group assignment) at any time after enrollment/randomization, even if no study intervention has been administered, will be recorded. | Enrollment/Randomization to Day 28 (or hospital discharge, if earlier) |
| Number of Participants with Serious Adverse Events | A serious adverse event (SAE) is an AE, regardless of causality, that fulfills one or more protocol defined criteria for being serious. | Enrollment/Randomization to Day 35 Follow-up |
| Change from Baseline in Clinical Chemistry Parameters | Baseline to Day 7 | |
| Change from Baseline in Hematology Parameters | Baseline to Day 7 | |
| Change from Baseline in Vital Signs | Baseline to Day 7 | |
| Change from Baseline in Pulse Oximetry and Oxygen Delivery Measurements | Baseline to Day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Development of Severe Acute Pancreatitis | Defined as >48 hours persistent organ failure | Day 1 to Day 28 (or hospital discharge, if earlier) |
| Development of New Onset Moderately Severe Acute Pancreatitis |
Not provided
Key Inclusion Criteria:
Key Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kelly Abernathy | Contact | 9194609500 | kabernathy@arrivobio.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Recruiting | Little Rock | Arkansas | 72205 | United States |
There is no plan to make individual participant data (IPD) available to other researchers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Defined as transient organ failure and/or local or systemic complications without persistent organ failure
| Day 1 to Day 28 (or hospital discharge, if earlier) |
| Development of Pancreatic Necrosis | As identified on CECT/CEMRI imaging; may be further sub-grouped into <30%, 30%-50%, and >50% pancreatic necrosis, if data allow. | Baseline to Day 60 Follow-up |
| Development of Local Complications of Acute Pancreatitis | As identified on CECT/CEMRI imaging; may be further sub-grouped by type of complication, if data allow. | Baseline to Day 60 Follow-up |
| Mortality due to acute pancreatitis and/or complications secondary to acute pancreatitis | Death caused by acute pancreatitis and/or complications secondary to acute pancreatitis | Day 1 to Day 60 Follow-up |
| Mortality due to any cause | Death due to any cause | Day 1 to Day 60 Follow-up |
| Days in Hospital | Day 1 through Day 28 (or hospital discharge, if earlier) |
| Re-hospitalization for acute pancreatitis or related complications | Number of participants re-hospitalized for acute pancreatitis or related complications out of total participants who are discharged. | From initial hospital discharge to Day 35 Follow-up |
| Length of Stay in Intensive Care Unit | Day 1 through Day 28 (or hospital discharge, if earlier) |
| Development of New Onset Infection | May be further sub-grouped by: pancreatic, peripancreatic, and extra-pancreatic infections, as data allow. | Day 1 to Day 28 (or hospital discharge, if earlier) |
| Change in Modified Marshall Score | From Baseline through Day 28 (or hospital discharge, if earlier) |
| Change in Sequential Organ Failure Assessment (SOFA) Score | From Baseline through Day 28 (or hospital discharge, if earlier) |
| Change in Systemic Inflammatory Response Syndrome (SIRS) Assessment | From Baseline through Day 28 (or hospital discharge, if earlier) |
| Change in Abdominal Pain Numeric Rating Score | From Baseline through Day 28 (or hospital discharge, if earlier) |
| Change in Computed Tomography Severity Index (CTSI) Score for Pancreatitis | From Baseline through Day 60 Follow-up |
| Change in Modified Computed Tomography Severity Index (mCTSI) Score for Pancreatitis | From Baseline through Day 60 Follow-up |
| Keck Hospital of USC and LA County Hospital | Recruiting | Los Angeles | California | 90033 | United States |
|
| University of Colorado Anschutz Medical Campus | Recruiting | Aurora | Colorado | 80045 | United States |
|
| University of Florida Health | Recruiting | Gainesville | Florida | 32608 | United States |
|
| Orlando Health | Recruiting | Orlando | Florida | 32806 | United States |
|
| UI Health, University of Illinois Chicago Hospital Health Sciences System | Recruiting | Chicago | Illinois | 60612 | United States |
|
| Indiana University Health University Hospital | Withdrawn | Indianapolis | Indiana | 46202 | United States |
| Johns Hopkins Hospital | Recruiting | Baltimore | Maryland | 21287 | United States |
|
| Henry Ford Hospital | Recruiting | Detroit | Michigan | 48202 | United States |
|
| Dartmouth Hitchcock Medical Center | Recruiting | Lebanon | New Hampshire | 03756 | United States |
|
| NYU Langone Medical Center | Recruiting | New York | New York | 10016 | United States |
|
| Lisie Hospital | Recruiting | Kochi | Kerala | 682018 | India |
|
| Christian Medical College (CMC) Vellore, Ranipet Campus | Recruiting | Vellore | TamiNadu | 632517 | India |
|
| Postgraduate Institute of Medical Education and Research | Not yet recruiting | Chandigarh | India |
|
| All India Institute of Medical Sciences | Recruiting | Delhi | 110029 | India |
|
| Govind Ballabh Pant Institute of Postgraduate Medical Education and Research | Recruiting | New Delhi | 110002 | India |
|
| ID | Term |
|---|---|
| D010195 | Pancreatitis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided